Rh2 and its aglycone aPPD in combination therapy with docetaxel - pre-clinical evaluation in a PC-3 human prostate

Rh2 and its aglycone aPPD in combination therapy with docetaxel - pre-clinical evaluation in a PC-3 human prostate

Show other versions (2)

PURPOSE: The purpose of this thesis is to establish the therapeutic potential of ginsenoside Rh2, a 20(S)-protopanaxadiol type and its aglycone aPPD, two gastrointestinal metabolites of Panax Ginseng C.A. Meyer, for use in advanced prostate cancer. This thesis assesses (i) the pharmacokinetics, biod...

Full description

Bibliographic Details
Main Author:	Musende, Alain G.
Format:	Others
Language:	English
Published:	University of British Columbia 2009
Online Access:	http://hdl.handle.net/2429/5740

Similar Items

Rh2 and its aglycone aPPD in combination therapy with docetaxel - pre-clinical evaluation in a PC-3 human prostate
by: Musende, Alain G.
Published: (2009)

Rh2 and its aglycone aPPD in combination therapy with docetaxel - pre-clinical evaluation in a PC-3 human prostate
by: Musende, Alain G.
Published: (2009)

Multiple mechanisms of apoptosis induced by 20(S)-protopanaxadiol (aPPD) in glioma cells
by: Liu, Guo Yu
Published: (2009)

Isolated ginsenosides aPPD and aPPT induced cytochrome P450 1 A 1 mRNA expression
by: Zhao, Yang
Published: (2010)

POSSIBILITIES OF A COMBINATION OF DOCETAXEL WITH ANDROGEN DEPRIVATION IN INITIAL THERAPY OF HORMONESENSITIVE PROSTATE CANCER
by: A. A. GRITSKEVICH, et al.
Published: (2017-06-01)

Sensitizing the cytotoxic action of Docetaxel induced by Pentoxifylline in a PC3 prostate cancer cell line
by: Martha E. Cancino-Marentes, et al.
Published: (2021-03-01)

Effects of bisphosphonates alone and in combination with docetaxel : Studies in Prostate Cancer
by: Coxon, Jonathan Philip
Published: (2007)

Synthesis of the aglycones of pseudopterosins
by: Pontiroli, Alessandro
Published: (1997)

Synthesis of the staurosporine aglycone
by: Rahimtoola, Kulsum Farouq
Published: (1990)

Combination Effects of Docetaxel and Doxorubicin in Hormone-Refractory Prostate Cancer Cells
by: Eleftheria Tsakalozou, et al.
Published: (2012-01-01)

Undifferentiated prostate cancer treated with docetaxel
by: Masaki Kobayashi, et al.
Published: (2020-07-01)

Pharmacokinetics of acteoside and its aglycone hydroxytyrosol in rats
by: Yu-Tse Wu, et al.
Published: (2008)

The Effects of Matrine in Combination with Docetaxel on Castration-Resistant (Androgen-Independent) Prostate Cancer
by: Li Q, et al.
Published: (2019-12-01)

Total synthesis of the pseudopterosin aglycone
by: Kohler, Andrew Douglas
Published: (1994)

Synthesis of Cytopiloyne Aglycone and Derivatives
by: Huan-Song Chen, et al.
Published: (2011)

Dietary isoflavones : aglycones and glycosides
by: Tan, Jingjun
Published: (2011)

Effectiveness of Docetaxel for Metastatic Hormone-sensitive Prostate Cancer in Clinical Practice
by: Maria Elisabeth Lendorf, et al.
Published: (2021-02-01)

Clinical outcomes in castration resistant prostate cancer patients treated with docetaxel
by: Shian-Shiang Wang, et al.
Published: (2016-06-01)

siRNA-Mediated Silencing of CIP2A Enhances Docetaxel Activity Against PC-3 Prostate Cancer Cells
by: Saiedeh Razi Soofiyani, et al.
Published: (2017-12-01)

Purified Protein Derivative - PPD
by: Anastácio Q. Sousa, et al.

Post-docetaxel therapy in castration resistant prostate cancer – the forest is growing in the desert
by: Amelia Altavilla, et al.
Published: (2012-06-01)

Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer.
by: ShengYu Ku, et al.
Published: (2014-01-01)

Potential use of Aneustat for improvement of docetaxel-based therapy of advanced prostate cancer
by: Qu, Sifeng
Published: (2017)

Core shell lipid-polymer hybrid nanoparticles with combined docetaxel and molecular targeted therapy for the treatment of metastatic prostate cancer
by: Qi Wang, et al.
Published: (2017-07-01)

Docetaxel in the treatment of hormone-resistant prostate cancer
by: B. V. Bukharkin, et al.
Published: (2020-02-01)

Clinical Study of Docetaxel, Prednisone and Bevacizunab in the Treatment of Hormone Refractory Prostate Cancer
by: Theodore D. Koreckij, et al.
Published: (2015-06-01)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
by: Filippo Francini, et al.
Published: (2011-01-01)

Studies on the biosynthesis of the aglycone of progoitrin in rutabaga /
by: Lee, Arthur Chiu-Jong,1932-
Published: (1970)

Total Syntheses of Fastigiatine and the Hibarimicin Aglycons
by: Liau, Brian Bor-Jen
Published: (2013)

Synthetic approaches to the pseudopterosin A aglycone
by: King, Clare Dawn
Published: (2001)

Synthesis of the aglycon of scorzodihydrostilbenes B and D
by: Katja Weimann, et al.
Published: (2019-03-01)

Efficacy and Safety of Androgen-Deprivation Therapy Combined with Docetaxel Plus Prednisone in High-Burden Metastatic Hormone-Sensitive Prostate Cancer
by: Hu L, et al.
Published: (2020-06-01)

Synergistic Enhancement of Cancer Therapy Using a Combination of Ceramide and Docetaxel
by: Li-Xia Feng, et al.
Published: (2014-03-01)

Study of drug release from an elementary osmotic pump tablet by NMR imaging
by: Musende, Alain
Published: (2009)

Study of drug release from an elementary osmotic pump tablet by NMR imaging
by: Musende, Alain
Published: (2009)

Efficacy and Prognostic Factors of Docetaxel Combined with ADT on Metastatic Hormone-sensitive Prostate Cancer Patients
by: LIU Sanhe, et al.
Published: (2019-06-01)

NEW TRENDS IN THE USE OF TAXOTERE (DOCETAXEL) IN PROSTATE CANCER
by: O. B. Karyakin, et al.
Published: (2014-08-01)

Docetaxel (Tautax) in the treatment of hormone-refractory prostate cancer
by: I. G. Rusakov, et al.
Published: (2020-02-01)

Epithelial-Mesenchymal Transition in Docetaxel-Resistant Prostate Cancer
by: Camila Libardi do Amaral
Published: (2017-06-01)

NEW TRENDS IN THE USE OF TAXOTERE (DOCETAXEL) IN PROSTATE CANCER
by: O. B. Karyakin, et al.
Published: (2014-08-01)